Recombinant ADAMTS13

DRUG2 trials

Sponsors

Baxalta now part of Shire, Takeda

Conditions

Hereditary Thrombotic Thrombocytopenic Purpura (TTP)Thrombotic Thrombocytopenic Purpura (TTP)

Phase 1

Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

CompletedNCT02216084

Baxalta now part of ShireHereditary Thrombotic Thrombocytopenic Purpura (TTP)

Start: 2014-09-30End: 2016-02-22Updated: 2021-05-05

Unknown Phase

A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

RecruitingNCT06441578

TakedaThrombotic Thrombocytopenic Purpura (TTP)

Start: 2024-05-30End: 2032-09-30Target: 40Updated: 2025-10-07

Related Papers

Population Pharmacokinetics and Exposure-Response Analyses to Demonstrate the Link of Causality between ADAMTS13 and the Clinical Effects of Recombinant ADAMTS13 Compared to Plasma-Based Therapies

Blood2023-11-022 citations

Recombinant ADAMTS13 for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura: Design of a Phase 3b Open-Label Continuation Study of Prophylactic and on-Demand Treatment

Blood2021-11-058 citations

Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura

Blood2017-09-15256 citations